Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4037018 | 0.84 | EPHX2 (0.73) | EPHX2LMNAMEN1KMT2AHTT | |
| SCHEMBL4100281 | 0.84 | EPHX2 (0.72) | EPHX2LMNAMEN1KMT2AHTT | |
| SCHEMBL4099352 | 0.82 | EPHX2 (0.70) | EPHX2LMNAMEN1KMT2AHTT | |
| SCHEMBL12884438 | 0.78 | EPHX2 (0.63) | EPHX2LMNAMEN1KMT2AHTT | |
| SCHEMBL4015835 | 0.74 | EPHX2 (0.76) | EPHX2 | |
| SCHEMBL3622016 | 0.74 | EPHX2 (0.58) | EPHX2HTTKDM4EHSD11B1ALDH1A1 | |
| SCHEMBL26499136 | 0.74 | CACNA1H (0.81) | EPHX2LMNAKMT2AKDM4EALDH1A1 | |
| SCHEMBL12443646 | 0.74 | LMNA (0.71) | EPHX2LMNAMEN1KMT2AHTT | |
| SCHEMBL21738322 | 0.74 | EPHX2 (0.58) | EPHX2LMNAMEN1KMT2AHTT | |
| SCHEMBL3939854 | 0.73 | EPHX2 (0.61) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009022171-A1 | PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | EPHX2 3669/4885LMNA 2739/4885MEN1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.